EPISODE · Aug 23, 2023 · 15 MIN
#14 – Simon Arkell, CEO and Co-Founder of Synthetica Bio
from BioBreakthroughs · host Slice of Healthcare LLC
Join us on the latest episode! Our Guest: Simon Arkell, CEO and Co-Founder of Synthetica BioWhat you'll get out of this episode:- Simon Arkell, CEO of Synthetica Bio, sheds light on biopharma's future- Originally an Australian athlete, Arkell became a U.S.-based entrepreneur, focusing on machine learning, data analytics, and patient care.- His standout contribution was through DeepLens in precision oncology.- Synthetica Bio aims to provide advanced data solutions in biopharma using generative AI, addressing the industry's data analysis challenges.- Despite abundant data, biopharma grapples with analysis bottlenecks due to task-specific traditional models.- Synthetica Bio differentiates itself with versatile data interpretation using generative AI and a unique cloud-based microservices architecture.- With backing from major venture capitalists and strategic partnerships, Synthetica Bio is on track for significant industry innovation.- Overall, Synthetica Bio is driving transformation in biopharma, maximizing generative AI's potential.To learn more about Synthetica Bio: https://syntheticabio.ai/Our sponsors for this episode are:Sage Growth Partners https://sage-growth.com/FlipMD by GoodRX https://www.goodrx.com/Quantum Health https://quantum-health.com/
What this episode covers
Join us on the latest episode! Our Guest: Simon Arkell, CEO and Co-Founder of Synthetica BioWhat you'll get out of this episode:- Simon Arkell, CEO of Synthetica Bio, sheds light on biopharma's future- Originally an Australian athlete, Arkell became a U.S.-based entrepreneur, focusing on machine learning, data analytics, and patient care.- His standout contribution was through DeepLens in precision oncology.- Synthetica Bio aims to provide advanced data solutions in biopharma using generative AI, addressing the industry's data analysis challenges.- Despite abundant data, biopharma grapples with analysis bottlenecks due to task-specific traditional models.- Synthetica Bio differentiates itself with versatile data interpretation using generative AI and a unique cloud-based microservices architecture.- With backing from major venture capitalists and strategic partnerships, Synthetica Bio is on track for significant industry innovation.- Overall, Synthetica Bio is driving transformation in biopharma, maximizing generative AI's potential.To learn more about Synthetica Bio: https://syntheticabio.ai/Our sponsors for this episode are:Sage Growth Partners https://sage-growth.com/FlipMD by GoodRX https://www.goodrx.com/Quantum Health https://quantum-health.com/
NOW PLAYING
#14 – Simon Arkell, CEO and Co-Founder of Synthetica Bio
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.